Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Agnese Gugliandolo, Federica Longo, Maria Giovanna Marrosu, Giovanni Luigi Mancardi, Ilaria Gandoglia, Maurizio Melis, Fabrizio Lo Giudice, Placido Bramanti & Emanuela Mazzon. (2018) A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients. Therapeutics and Clinical Risk Management 14, pages 1765-1788.
Read now
Read now
Mark A. Matson, Thomas R. Zimmerman$suffix/text()$suffix/text(), Dianne Tuccillo, Yongqiang Tang & Aaron Deykin. (2011) Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation. Current Medical Research and Opinion 27:12, pages 2271-2278.
Read now
Read now
Edward J Fox. (2010) Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis. Expert Review of Neurotherapeutics 10:12, pages 1789-1797.
Read now
Read now
Brandon A Brown. (2009) Natalizumab in the treatment of multiple sclerosis. Therapeutics and Clinical Risk Management 5, pages 585-594.
Read now
Read now
Articles from other publishers (25)
Shiva Narang & Tanmay Diliprao Laxane. 2022. Infections and Pregnancy. Infections and Pregnancy
51
62
.
Francesco Patti, Giovanni Bosco Zimatore, Vincenzo Brescia Morra, Umberto Aguglia, Roberto Bruno Bossio, Roberto Marziolo, Paola Valentino, Clara Grazia Chisari, Antonio Capacchione & Mario Zappia. (2020) Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. Journal of Neurology 267:6, pages 1812-1823.
Crossref
Crossref
Xavier MontalbanThomas P. LeistBruce A. CohenHarold MosesJackie CampbellChristine HickingFernando DangondGiancarlo Comi, Paolo Gallo, Carlo Pozzilli, Claudio Gasperini, Vincenzo Brescia Morra, Alexey N Boyko, Olga Amelina, Sergey V Kotov, Lilia Novikova, Olga Patrusheva, Igor Zavalishin, Farid Khabirov, Natalia Maslova, Nadezda Malkova, Irina E Poverennova, Xavier Montalban, Sergio Martinez Yelamos, Guillermo Izquierdo, Oscar Fernandez, Alfredo Rodriguez-Antiguedad, Angel Perez Sempere, Rafael Arroyo, Bonaventura Casanova, Manual Arias, Mark Cascione, Bruce Arnold Cohen, Edward Fox, Regina Berkovich, Michael Kaufman, Thomas Leist, Dina Jacobs, Tamara Miller, Harold Moses, Michael Racke, George Hutton, Barry Singer, Kiren Kresa-Reahl, Emily Pharr, Jonathan L Carter, Jeanette Wendt, Rup Tandan, Roberto Bomprezzi, Corey Ford, Stephen Kamin, Misha Pless, George P Garmany, Suzanne Gazda, Jeffrey English, Barbara Green, Dennis Garwacki, Jeffrey Gould & Chris LaGanke. (2018) Cladribine tablets added to IFN-β in active relapsing MS. Neurology Neuroimmunology & Neuroinflammation 5:5.
Crossref
Crossref
Bernadette Porter. (2017) Commentary on “Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection” by Coghe et al.. Multiple Sclerosis Journal 24:2, pages 233-235.
Crossref
Crossref
Luis Ramos, Carmen Busca & Angel Robles. (2018) Esteatonecrosis aséptica en una paciente con esclerosis múltiple y tratamiento con interferón beta 1b. Medicina Clínica 150:3, pages 122.
Crossref
Crossref
Luis Ramos, Carmen Busca & Angel Robles. (2018) Aseptic steatonecrosis in a patient with multiple sclerosis with interferon-beta 1b treatment. Medicina Clínica (English Edition) 150:3, pages 122.
Crossref
Crossref
Li-Wen Lee, Hung-Jen Lin & Sheng-Teng Huang. (2018) Management of IFN-beta-induced flu-like symptoms with Chinese herbal medicine in a patient with multiple sclerosis: A case report. Complementary Therapies in Medicine 36, pages 123-128.
Crossref
Crossref
Maëlle Voirin. (2018) Dispensation des traitements de fond de la sclérose en plaques à l’officine. Actualités Pharmaceutiques 57:573, pages 26-30.
Crossref
Crossref
Doriana Landi, Maria Albanese, Fabio Buttari, Fabrizia Monteleone, Laura Boffa, Silvia Rossi, Caterina Motta, Elisa Puma & Diego Centonze. (2017) Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study. PLOS ONE 12:7, pages e0165415.
Crossref
Crossref
R. Gouider. (2017) Can we discontinue disease-modifying treatments in multiple sclerosis patients? Comments. Revue Neurologique 173:1-2, pages 44-46.
Crossref
Crossref
Irene Cortese & Avindra Nath. 2017. Neuroimmune Pharmacology. Neuroimmune Pharmacology
713
736
.
Mitra Habibi & Huda-Marie Kuttab. (2016) Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems. American Journal of Health-System Pharmacy 73:11, pages 811-819.
Crossref
Crossref
Martin Langeskov-Christensen, Tue Kjølhede, Egon Stenager, Henrik Boye Jensen & Ulrik Dalgas. (2016) Can aerobic exercise alleviate flu-like symptoms following interferon beta-1a injections in patients with multiple sclerosis?. Journal of the Neurological Sciences 365, pages 114-120.
Crossref
Crossref
Diego Bertoli, Federico Serana, Alessandra Sottini, Cinzia Cordioli, Davide Maimone, Maria Pia Amato, Diego Centonze, Ciro Florio, Elisa Puma, Ruggero Capra & Luisa Imberti. (2015) Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene. PLOS ONE 10:8, pages e0135441.
Crossref
Crossref
Maria Luisa Sánchez Masid, Rosalía Horno Ocaña, María Jesús Díaz Gil, Maria Concepción Ramírez Ramos, Matilde Escutia Roig, Maria Rosario Coll Carreño, Jaime Cordero Morales, Maria Luisa Vergara Carrasco, Leonor Mariana Rubio Hidalgo, Ana Maria Bernad Felices, Adela Harto Castaño, Purificación Castañeda Romero, Pablo Francoli Martinez & Rainel Sánchez-De la Rosa. (2015) A Patient Care Program for Adjusting the Autoinjector Needle Depth According to Subcutaneous Tissue Thickness in Patients With Multiple Sclerosis Receiving Subcutaneous Injections of Glatiramer Acetate. Journal of Neuroscience Nursing 47:1, pages E22-E30.
Crossref
Crossref
Mary L. Filipi, Jill Beavin, Raquel T. Brillante, Kathleen Costello, Gail C. Hartley, Kay Hartley, Marie Namey, Shirley O'Leary & Gina Remington. (2014) Nurses’ Perspective on Approaches to Limit Flu-Like Symptoms During Interferon Therapy for Multiple Sclerosis. International Journal of MS Care 16:1, pages 55-60.
Crossref
Crossref
José Fidel Baizabal-Carvallo, Joseph Jankovic & Jordan Feld. (2013) Flu-like Symptoms and Associated Immunological Response Following Therapy with Botulinum Toxins. Neurotoxicity Research 24:2, pages 298-306.
Crossref
Crossref
Thomas M. Stewart & Zung Vu Tran. (2012) Injectable Multiple Sclerosis Medications. International Journal of MS Care 14:1, pages 46-53.
Crossref
Crossref
Volker Limmroth, Norman Putzki & Norman J. Kachuck. (2011) The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Therapeutic Advances in Neurological Disorders 4:5, pages 281-296.
Crossref
Crossref
Claudio Solaro & Michele Messmer Uccelli. (2011) Management of pain in multiple sclerosis: a pharmacological approach. Nature Reviews Neurology 7:9, pages 519-527.
Crossref
Crossref
Jose F. Baizabal-Carvallo, Joseph Jankovic & Eric Pappert. (2011) Flu-like symptoms following botulinum toxin therapy. Toxicon 58:1, pages 1-7.
Crossref
Crossref
Laura Gabaldón Torres, M. José Aguilar-Amat Prior, Celia Oreja-Guevara & Exuperio Díez-Tejedor. (2010) Retinopatía y nefropatía en paciente con esclerosis múltiple en tratamiento con interferón-β. Medicina Clínica 134:11, pages 511.
Crossref
Crossref
Elliot M. Frohman, Gary Cutter, Gina Remington, Hongjiang Gao, Howard Rossman, Bianca Weinstock-Guttman, Jacqueline E. Durfee, Amy Conger, Ellen Carl, Katherine Treadaway, Eric Lindzen, Amber Salter, Teresa C. Frohman, Anjali Shah, Angela Bates, Jennifer L. Cox, Michael G. Dwyer, Olaf Stuve, Benjamin M. Greenberg, Michael K. Racke & Robert Zivadinov. (2010) A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders 3:1, pages 15-28.
Crossref
Crossref
Melody Ryan. (2009) Drug Therapies for the Treatment of Multiple Sclerosis. Journal of Infusion Nursing 32:3, pages 137-144.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:3.
Crossref
Crossref